British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
复制标题
DOI：
10.1111/j.1365-2133.2005.06893.x
复制
发表时间：
2005-09-01
影响因子：
10.3
通讯作者：
Ormerod, AD
中科院分区：
文献类型：
--
作者：
Smith, CH;Anstey, AV;Ormerod, AD
牛皮癣是一种常见的、持续的、复发的炎症性皮肤病，可伴有显著的发病率。银屑病患者的生活质量研究表明，银屑病对患者的负面影响与癌症、关节炎和心脏病患者的负面影响相当。严重疾病患者约占所有牛皮癣患者的20-30%，通常需要全身治疗，并且是卫生服务的主要经济负担。所有针对严重疾病的标准全身疗法都有可能产生重大的长期毒性，许多疗法都很昂贵，而且一部分患者患有治疗耐药疾病。生物疗法或“生物制剂”描述了旨在阻断银屑病发病机制中重要的特定分子步骤的药物，并在过去3-5年中作为潜在有价值的替代治疗方案出现。目前，银屑病的生物治疗包括两大类：(i)靶向细胞因子肿瘤坏死因子(TNF)-α的药物（如依那西普、英夫利昔单抗、阿达木单抗）和（ii）靶向T细胞或抗原呈递细胞的药物（如依法珠单抗、阿法西普）。其中，依那西普（Enbrel®）和依法单抗（Raptiva®）于2004年在英国获得许可，用于治疗中度至重度牛皮癣患者。©2005英国皮肤科医师协会。
Psoriasis is a common, persistent, relapsing inflammatory skin disease that can be associated with significant morbidity. Quality of life studies in psoriasis reveal a negative impact on patients comparable with that seen in cancer, arthritis and heart disease. Patients with severe disease constitute approximately 20-30% of all patients with psoriasis, often require systemic treatment, and represent a major economic burden to the Health Service. All standard systemic therapies for severe disease are associated with the potential for major long-term toxicity, many are expensive, and a proportion of patients has treatment-resistant disease. Biological therapies or'biologics' describe agents designed to block specific molecular steps important in the pathogenesis of psoriasis and have emerged over the last 3-5 years as potentially valuable alternative therapeutic options. Currently, biological therapies for psoriasis comprise two main groups:(i) agents targeting the cytokine tumour necrosis factor (TNF)-α (eg etanercept, infliximab, adalimumab) and (ii) agents targeting T cells or antigen-presenting cells (eg efalizumab, alefacept). Two of these, etanercept (Enbrel®) and efalizumab (Raptiva®) were licensed in 2004 in the UK for patients with moderate to severe psoriasis.© 2005 British Association of Dermatologists.